An observational study in Sepsis - to Reduce Mortality in the Intensive Care Unit and Burns Involving 20% or More of Body Surface, sponsored by Dohern Kym. Enrolling by invitation at 1 site in South Korea. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Dohern Kym · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Burns with a site in Korea, Republic of — 9 open to participants now, 9 under way, none of them phase 3. Burns · Korea, Republic of.
Among the 29 studies in Burns with a site in Korea, Republic of, this one is one of 5 that started in 2025, is one of 8 observational ones, and was the 25th registered.
906 studies on the registry are indexed under Burns; 165 are open to participants now.
Browse Burns studies →9 of the 29 studies in Burns with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Cho Yoon soo · Sites in Korea, Republic of
Ages 19–65
Hangang Sacred Heart Hospital · Sites in Korea, Republic of
Ages 19–65
Dohern Kym · Sites in Korea, Republic of
Ages 18+
Hangang Sacred Heart Hospital · Sites in Korea, Republic of
Ages 18–75
Hangang Sacred Heart Hospital · Sites in Korea, Republic of
Ages 18–75
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 87 Burns studies recruiting now, 38 (44%) set no upper age limit and 38 (44%) stop at 75 or younger; 17 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 165 is above the median of 64 across 163 observational studies indexed under Burns.
Median enrollment 40 across the 21 interventional studies, 94 across the 8 observational. Of the 13 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 29 have an industry lead sponsor. The 7 most frequent:
Dohern Kym is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Dohern Kym has 2 studies filed under Burns — fewer than ten, so there is no comparison to draw.
2 of the studies in Burns with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07578753Hangang Sacred Heart HospitalClinical Effectiveness of Robot-assisted Gait Training in Patients With Lower Limb Burns Accompanied by Fractures: Pilot Study | 2026-12-25 |
| NCT07060560Dohern KymPresepsin Diagnostic Performance in Severe Burn Sepsis | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 29 studies in Burns with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective diagnostic accuracy study evaluates the performance of presepsin and C-reactive protein (CRP) as early biomarkers for suspected sepsis in adult burn patients. From January 2021 to December 2022, 370 patients with ≥20% total body surface area burns admitted to the Burn Intensive Care Unit at Hallym University Hangang Sacred Heart Hospital were screened; 221 met inclusion criteria. At each clinical suspicion of sepsis (≥2 SIRS criteria), venous blood was drawn for simultaneous measurement of presepsin (via chemiluminescent immunoassay) and CRP (via immunoturbidimetric assay). Diagnostic accuracy will be quantified by sensitivity, specificity, positive/negative predictive values, and area under the ROC curve. The goal is to determine whether presepsin outperforms CRP for early sepsis detection in severe burn patients.
Background and Rationale Sepsis is a leading cause of mortality in patients with severe burns, yet its early diagnosis is challenging. The systemic inflammatory response triggered by the burn injury itself often mimics the clinical signs of sepsis, confounding diagnosis and leading to delayed or unnecessary antibiotic use. Conventional biomarkers like C-reactive protein (CRP) and procalcitonin (PCT) lack specificity in this population, as they are elevated by the sterile inflammation from the burn itself. This study aims to overcome these limitations by evaluating the diagnostic utility of a multi-biomarker panel, analyzing their dynamic changes over time, and leveraging machine learning to develop a more accurate and interpretable diagnostic model for sepsis in burn patients.
Study Design and Objectives This is a single-center, prospective observational cohort study conducted at the Burn Intensive Care Unit (BICU) of Hallym University Hangang Sacred Heart Hospital. The study will run from September 2025 to December 2027.
Primary Objective: To evaluate the diagnostic accuracy (sensitivity, specificity, AUC) of a multi-biomarker panel-comprising Serum Amyloid A (SAA), Procalcitonin (PCT), Presepsin (PSP), and CRP-for diagnosing sepsis in adult burn patients, using the Sepsis-3 criteria as the reference standard.
Secondary Objectives: To compare the diagnostic performance of the multi-biomarker panel against individual biomarkers and standard clinical severity scores (e.g., SOFA score).
To assess the panel's ability to predict disease severity and mortality (28-day and 90-day).
To develop a predictive model for sepsis using machine learning and interpret the model's decisions using SHAP (SHapley Additive exPlanations) analysis.
Methods and Analysis Data and Sample Collection: For enrolled patients, comprehensive clinical data-including demographics, burn characteristics (%TBSA, inhalation injury), severity scores (SOFA, APACHE II), and microbiological results-will be collected. Blood samples for biomarker analysis will be collected upon ICU admission (baseline), at the time of clinical suspicion of sepsis, and serially thereafter (daily if possible) for a minimum of seven days to capture the temporal dynamics of the biomarkers.
Biomarker Panel: The core panel includes SAA, PCT, PSP, and CRP, supplemented by routine hematological markers like WBC, platelet count, NLR, and PLR.
Statistical and Advanced Analytical Plan:
Diagnostic Accuracy: Traditional statistical methods, including ROC curve analysis and DeLong's test, will be used to compare the diagnostic performance of individual and combined biomarkers.
Dynamic Analysis: To analyze the longitudinal biomarker data, generalized estimating equations (GEE) or linear mixed models (LMM) will be employed. This will allow for the quantitative assessment of biomarker trends (e.g., rate of change) and their association with sepsis diagnosis and prognosis.
Machine Learning and Interpretation: A key component of this study is the development of advanced predictive models using machine learning algorithms (e.g., Random Forest, XGBoost). To address the "black box" nature of these models, we will utilize SHAP analysis to provide transparent interpretations. This will quantify the precise contribution of each biomarker to individual patient predictions, offering deeper clinical insights into the pathophysiological state.
Sample Size: A total of 165 patients will be recruited. This sample size was calculated using G*Power software to achieve 80% power at a significance level of 0.05, assuming an expected sensitivity of 90% and specificity of 80% for the multi-biomarker panel in ROC analysis.
Adults (≥18 years) with severe thermal burns (TBSA ≥20%) admitted to a single-center BICU who developed clinically suspected sepsis (≥2 SIRS criteria) during the enrollment period; all participants underwent standardized blood sampling for presepsin and CRP assays
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adults ≥18 years with ≥20% TBSA burns admitted to the Burn Intensive Care Unit who developed clinically suspected sepsis (≥2 SIRS criteria)
Diagnostic accuracy of presepsin for early sepsis detection
Sensitivity and specificity of presepsin (measured by chemiluminescent immunoassay on PATHFAST analyzer) for diagnosing clinically suspected sepsis (≥2 SIRS criteria) in adult burn patients.
Time frame: At the time of clinical suspicion of sepsis (Day 0), and daily for the following 7 days (Day 1 through Day 7).
Area under the ROC curve (AUC) for presepsin versus CRP
Comparison of AUCs for presepsin and CRP using DeLong's test to assess which biomarker better discriminates sepsis versus non-sepsis.
Time frame: Through study completion, an average of 1.5 years.
Started Aug 2025 (actual). Primary completion is estimated for Dec 2027, 28 months after the start.
Of 58 non-industry observational studies under Burns, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 56. This study's planned 28 months is close to that.
Counting every sponsor, half of 70 studies reached it within 24 months; a quarter within 14 and three quarters within 56.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Oct 2026 → Dec 2027 and completion Oct 2026 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dohern Kym